AC Immune to Host Key Opinion Leader Event: ‘Untangling’ Tau Pathology to Treat Alzheimer’s and Neurodegenerative Diseases
Neurodegenerative diseases, including Alzheimer’s disease, are associated with the presence of defective Tau protein in the brain. Imaging studies show that Tau pathology correlates strongly with the rate of cognitive decline, making Tau an important therapeutic target, as well as a promising biomarker for earlier diagnosis and tracking disease progression. Therefore, targeting Tau pathology is a key element of AC Immune’s Roadmap to Successful Therapies for Neurodegenerative Diseases. The Company’s unique approach targets the full spectrum of Tau pathology by detecting and inhibiting both early seeding and extracellular spreading of Tau with its best-in-class small molecules, antibodies and vaccines, as well as its cutting-edge Tau diagnostic agents. The event will include presentations from leading KOLs as well as a discussion of key preclinical and clinical data from AC Immune’s therapeutic development programs and an outline of key programs expected to enter late-stage development in the next two years.
Company and KOL presentations will be followed by an interactive roundtable discussion between the audience, Dr.
Key Opinion Leader Biographies
Dr.
Dr. Johnson has extensive experience in imaging research in neurodegenerative diseases, is a Principal Investigator of the Harvard Aging Brain Study, and oversees the brain PET imaging program at MGH, which includes active research programs in imaging of amyloid-beta and PHF Tau, as well as Lewy body diseases and 4R Tauopathies. Dr. Johnson leads the PET component of the A4 Study, as well as several other AD clinical trials. He leads the PET Unit of the
Dr. Johnson is a practicing Neurologist in Behavioral Neurology, Associate Physician in Neurology at
Dr. Stephens is a founder and the Chief Medical Officer and Head of Research and Development for
Before joining the current company, he was VP, Head Experimental Medicine Oncology/Diagnostic Imaging for Bayer Pharma. Dr. Stephens received an M.D. and a Ph.D. in biochemistry, biophysics and genetics from the
About
For further information, please contact:
| US Investors Joshua Drumm, Ph.D. AC Immune Investor Relations Phone: +1 646 876 5538 E-mail: joshua.drumm@acimmune.com |
US Media Katie Gallagher LaVoieHealthScience Phone: +1 617 792 3937 E-mail: kgallagher@lavoiehealthscience.com |
| Head of Global Communications Judith Moore AC Immune Phone: +44 7932 053 829 E-mail: judith.moore@acimmune.com |
European Investors & Media Chris Maggos LifeSci Advisors Phone: +41 79 367 6254 E-mail: chris@lifesciadvisors.com |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the
Source: AC Immune SA